Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,125 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Influenza Virus Vaccine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Study To Evaluate the Safety of Bivalent Vaccine

NCT00325481
View directory record Official record
Conditions
Healthy
Interventions
FluMist
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2007 · Synced Oct 15, 2026, 8:53 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines

NCT07493460
View directory record Official record
Conditions
Immunology, Healthy Adults
Interventions
trivalent inactivated influenza vaccine (TIV), nonavalent HPV vaccine (HPV), hepatitis A (HAV) vaccines, tetanus, diphtheria and acellular pertussis vaccine (Tdap)
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally

NCT00436046
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza virus vaccine (2006-2007 formulation), Type 1 interferon
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

NCT06178991
View directory record Official record
Conditions
Influenza, COVID-19
Interventions
Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 64 Years
Enrollment
8,795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
106
States / cities
Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety Study of Seasonal Influenza Vaccine by Jet Injection

NCT00987350
View directory record Official record
Conditions
Healthy Adults
Interventions
LectraJet, TIV by jet injection, Seasonal Trivalent Influenza Vaccine
Device · Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects

NCT01313962
View directory record Official record
Conditions
Influenza
Interventions
Flufirvitide-3 0.05 mg single dose, Flufirvitide-3, 0.1 mg single dose, Flufirvitide-3, 0.2 mg single dose, Flufirvitide-3, 0.4 mg single dose, Placebo
Drug · Other
Lead sponsor
Autoimmune Technologies, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2012 · Synced Oct 15, 2026, 8:53 AM EDT
Completed No phase listed Observational

Real-time Influenza Vaccine Surveillance

NCT01233388
View directory record Official record
Conditions
Vaccine Safety
Interventions
Text message surveillance
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

NCT01934127
View directory record Official record
Conditions
Influenza
Interventions
Investigational H7N1 vaccine GSK2789869A, Investigational H7N1 vaccine GSK2789868A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years to 64 Years
Enrollment
427 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
6
States / cities
Miami, Florida • Stockbridge, Georgia • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults

NCT00754455
View directory record Official record
Conditions
Influenza
Interventions
Influenza VLP Vaccine (recombinant), Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Pembroke Pines, Florida • Kansas City, Missouri • Warwick, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults

NCT00546585
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H7N7 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

NCT03895385
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults

NCT00853255
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

NCT02545543
View directory record Official record
Conditions
Influenza, Human
Interventions
Seqirus QIV, Comparator QIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
5 Years to 17 Years
Enrollment
2,278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
32
States / cities
Huntsville, Alabama • Madera, California • Ontario, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 15, 2026, 8:53 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

NCT07169318
View directory record Official record
Conditions
Influenza
Interventions
Placebo for VNT-101, VNT-101
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 15, 2026, 8:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

NCT07128615
View directory record Official record
Conditions
Influenza A
Interventions
AZD4117, AZD5315, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
14
States / cities
Long Beach, California • Rolling Hills Estates, California • Miami Lakes, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Immunization Delivery in Obstetrics and Gynecology Settings

NCT01565135
View directory record Official record
Conditions
Immunization Status Among Obstetrics and Gynecology Patients
Interventions
Multimodal Vaccine Program
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
15 Years and older · Female only
Enrollment
97,087 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

NCT03814720
View directory record Official record
Conditions
Influenza Infection
Interventions
VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

NCT02214225
View directory record Official record
Conditions
Influenza, Human
Interventions
Quadrivalent Influenza Vaccine (QIV), Trivalent Influenza Vaccine (TIV-1), Trivalent Influenza Vaccine (TIV-2)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
3,484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
33
States / cities
Huntsville, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01859143
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Trivalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Duration of Immune Response to Influenza Vaccination in Patients With RA

NCT02311855
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Influenza vaccine
Biological
Lead sponsor
Bassett Healthcare
Other
Eligibility
40 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A/H5N1/LT Dose Ranging Study

NCT00908687
View directory record Official record
Conditions
Pandemic Influenza
Interventions
A/H5N1, LT Adjuvant Patch
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
6
States / cities
Anaheim, California • Vallejo, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ACTIVATE in Public Housing

NCT06075732
View directory record Official record
Conditions
Pneumonia, Influenza, Varicella Zoster, Meningitis, COVID-19, Vaccine Hesitancy
Interventions
Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 15, 2026, 8:53 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older

NCT02464163
View directory record Official record
Conditions
Influenza
Interventions
Panblok, rHA adjuvant
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
9
States / cities
Mobile, Alabama • DeLand, Florida • Savannah, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 15, 2026, 8:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

H5N1 Milk Detection Study

NCT06850298
View directory record Official record
Conditions
Influenza
Interventions
Pasteurized milk contaminated with killed A(H5) virus
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 15, 2026, 8:53 AM EDT